methylprednisolone has been researched along with Cancer of Oropharnyx in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geisler, AN; Noor, SJ | 1 |
| Ho, WJ; Kang, H; Rooper, L; Sagorsky, S | 1 |
2 other study(ies) available for methylprednisolone and Cancer of Oropharnyx
| Article | Year |
|---|---|
Cutaneous Manifestations of EGFR-Inhibitors in African Americans and Treatment Considerations.
Topics: Anti-Bacterial Agents; Antineoplastic Agents, Immunological; Black or African American; Cetuximab; Drug Eruptions; Drug Therapy, Combination; ErbB Receptors; Humans; Male; Methylprednisolone; Middle Aged; Oropharyngeal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2020 |
A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Colitis; Diabetes Mellitus; Fatal Outcome; Humans; Hypothyroidism; Insulin; Ipilimumab; Male; Methylprednisolone; Nivolumab; Oropharyngeal Neoplasms; Papillomavirus Infections; Prednisone; Thyroxine | 2018 |